Trevi Health Capital

US HealthVest is an innovative behavioral healthcare firm that has redefined the psychiatric hospital space. De novo strategies and acquisitions of operating facilities with unrealized potential are the core of the US HealthVest business model. Each facility is structured to offer multiple service lines in order to serve the needs of specific patient population groups. The senior management team of US HealthVest has successfully built psychiatric hospital businesses which were acquired by public companies. Ascend Health was founded by Richard Kresch, M.D. in 2005 and was one of the largest private psychiatric hospital providers with nine freestanding facilities and nearly 900 beds. Ascend Health was sold to Universal Health Services (NYSE: UHS) in 2012. The predecessor company, Heartland Health Developments, also focused on psychiatric care and was sold to Psychiatric Solutions in 2004.

Manhattan Labs, established in 2008, aims to be a leading independent clinical laboratory in the New York City metropolitan area. The organization focuses on delivering high-quality, service-oriented medical diagnostic testing while utilizing advanced laboratory technology. Known for personalized service, Manhattan Labs emphasizes exceptional turnaround times and easy access to results, positioning itself as a benchmark for quality and service in the laboratory industry.

Paradigm Spine, LLC (Paradigm Spine) is a privately-held medical device company, engaged in the development of spinal implants for the spine and orthopedic markets. It develops non fusion spinal implants, motion preserving products and tissue sparing products. Paradigm Spine's product Coflex, an interspinous implant used in the treatment of facet arthosis and decompressive procedures. Its products are used for spinal stabilization, rebalances spinal segment and restores natural anatomical function. The company is headquartered in New York, the US. The company also focused on the development of DSS system, a minimally-invasive pedicle-screw based system, which received a European CE Mark in April 2007 and FDA market clearance in January 2008.

Small Bone Innovations (SBi) specializes in the development and manufacturing of medical devices aimed at small bones and joints, with a particular emphasis on trauma and arthroplasty. The company provides a range of implants designed for various anatomical areas, including the thumb, hand, wrist, elbow, foot, and ankle. Its product offerings include implants specifically designed to treat basal joint arthritis and those intended for replacing anatomic joint surfaces. SBi's innovations focus on preserving bone structure and minimizing disruption to collateral ligament origins and insertions, as well as soft skeletal implants, thereby enhancing surgical outcomes for patients with joint-related conditions.

MedAvante, Inc. specializes in technology-enabled signal detection solutions for clinical trials targeting central nervous system disorders on a global scale. The company offers various services, including the Virgil Investigative Study Platform for site-based assessments and MedAvante Central Ratings, which facilitates live assessments conducted by remote clinicians. Additionally, MedAvante provides scientific risk reduction services such as rater qualification and training, central review for monitoring assessments, and remote ratings to mitigate bias and variability in trial results. Founded in 2002 and based in Hamilton, New Jersey, MedAvante has established a reputation for delivering standardized and expert central raters who conduct live interviews with trial participants via videoconferencing or telephone, contributing to successful outcomes in numerous global trials. MedAvante operates as a subsidiary of WIRB - Copernicus Group, Inc.

Small Bone Innovations (SBi) specializes in the development and manufacturing of medical devices aimed at small bones and joints, with a particular emphasis on trauma and arthroplasty. The company provides a range of implants designed for various anatomical areas, including the thumb, hand, wrist, elbow, foot, and ankle. Its product offerings include implants specifically designed to treat basal joint arthritis and those intended for replacing anatomic joint surfaces. SBi's innovations focus on preserving bone structure and minimizing disruption to collateral ligament origins and insertions, as well as soft skeletal implants, thereby enhancing surgical outcomes for patients with joint-related conditions.

Optovue, Inc. is an ophthalmic device company that specializes in developing, manufacturing, and selling spectral-domain optical coherence tomography (OCT) devices. Founded in 2003 and based in Fremont, California, the company focuses on advancing diagnostic capabilities for ocular diseases. Its product lineup includes various imaging systems such as AngioVue for visualizing retinal blood flow, Avanti for assessing peripheral retina pathology, and iFusion, which combines OCT and fundus imaging. Additionally, Optovue offers iVue for comprehensive retina and cornea assessments, as well as cloud-based solutions like NetVue for image management. The company aims to enhance the diagnosis and treatment of conditions such as macular degeneration and diabetic retinopathy by providing high-resolution and high-density imaging technologies. Optovue collaborates with eye care professionals and clinical researchers to drive innovation in ocular imaging and improve patient outcomes.

Omeros Corporation is a Seattle-based biopharmaceutical company engaged in the discovery, development, and commercialization of small-molecule and protein therapeutics. The company focuses on large-market and orphan indications, particularly targeting inflammation, complement-mediated diseases, and disorders of the central nervous system. Omeros offers OMIDRIA, a product used during cataract surgery in the United States. Its clinical pipeline includes narsoplimab, a monoclonal antibody in Phase III trials for various conditions, including hematopoietic stem-cell transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy. Other clinical programs involve treatments for opioid and nicotine addiction, as well as compulsive disorders. Preclinical efforts include developing therapies for paroxysmal nocturnal hemoglobinuria and exploring a range of G protein-coupled receptors for various disorders. Founded in 1994, Omeros is committed to addressing significant unmet medical needs through its innovative therapeutic approaches.

Ikonisys, Inc. specializes in designing and manufacturing medical diagnostic products aimed at cancer diagnosis and genetic disorder detection in the United States and Europe. The company offers a range of innovative products, including the Ikoniscope Robotic Microscope, which automates slide handling, scanning, and real-time image analysis to minimize human error in testing. Key applications include oncoFISH bladder for analyzing urine samples, oncoFISH her2 for assessing HER2 status in breast tissue, and oncoFISH PTEN for detecting PTEN gene deletions in prostate biopsies. Additionally, Ikonisys provides FISH scanning applications for both cell suspensions and various tissue sections, along with the IkoniWAN Gateway, a remote access solution for digital microscopy systems. Founded in 1999 and headquartered in New Haven, Connecticut, Ikonisys is committed to advancing diagnostic medicine through early and non-invasive disease detection, thereby enhancing patient management.